Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab

[1]  M. Kudo,et al.  Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice , 2022, Hepatology research : the official journal of the Japan Society of Hepatology.

[2]  T. Ishikawa,et al.  The prognosis of elderly patients with hepatocellular carcinoma: A multi‐center 19‐year experience in Japan , 2022, Cancer medicine.

[3]  M. Kudo,et al.  Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study , 2022, Hepatology.

[4]  Y. Hiasa,et al.  Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study , 2022, Hepatology International.

[5]  Y. Hiasa,et al.  Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis , 2022, Hepatology research : the official journal of the Japan Society of Hepatology.

[6]  J. Bruix,et al.  BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. , 2021, Journal of hepatology.

[7]  M. Ebert,et al.  Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. , 2021, Journal of hepatology.

[8]  M. Kudo,et al.  Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience , 2021, Cancer reports.

[9]  M. Kudo.  Impact of Multi-Drug Sequential Therapy on Survival in Patients with Unresectable Hepatocellular Carcinoma , 2021, Liver Cancer.

[10]  S. Kakizaki,et al.  Lenvatinib for Hepatocellular Carcinoma: A Literature Review , 2021, Pharmaceuticals.

[11]  F. Piscaglia,et al.  Experience with regorafenib in the treatment of hepatocellular carcinoma , 2021, Therapeutic advances in gastroenterology.

[12]  K. Shirabe,et al.  The Role of the Albumin-Bilirubin Score for Predicting the Outcomes in Japanese Patients with Advanced Hepatocellular Carcinoma Treated with Ramucirumab: A Real-World Study , 2020, Oncology.

[13]  M. Kudo,et al.  Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2 , 2020, JHEP reports : innovation in hepatology.

[14]  J. Marrero,et al.  Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference , 2020, Hepatology.

[15]  Yulei N. Wang,et al.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.

[16]  P. Chow,et al.  IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. , 2020, Future oncology.

[17]  Xiao-Song Li,et al.  Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis , 2020, Bioscience reports.

[18]  M. Kudo,et al.  Biology and significance of alpha‐fetoprotein in hepatocellular carcinoma , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[19]  M. Esteller,et al.  Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials , 2019, British Journal of Cancer.

[20]  M. Esteller,et al.  Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials , 2019, British Journal of Cancer.

[21]  M. Kudo,et al.  Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study , 2019, Cancers.

[22]  M. Merad,et al.  β-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma. , 2019, Cancer discovery.

[23]  Y. Hiasa,et al.  Impact of albumin–bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time‐dependent receiver operating characteristic , 2019, Journal of gastroenterology and hepatology.

[24]  M. Kudo,et al.  Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[25]  Gisela Schwab,et al.  Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma , 2018, The New England journal of medicine.

[26]  M. Kudo,et al.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.

[27]  S. Imbeaud,et al.  Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. , 2017, Journal of hepatology.

[28]  M. Kudo,et al.  Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function , 2017, Liver Cancer.

[29]  M. Esteller,et al.  Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. , 2017, Gastroenterology.

[30]  F. Roudot-thoraval,et al.  Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. , 2017, Journal of hepatology.

[31]  L. Bolondi,et al.  Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis. , 2017, The Lancet. Oncology.

[32]  Masatoshi Kudo,et al.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[33]  L. Bolondi,et al.  Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib , 2016, Therapeutic advances in gastroenterology.

[34]  B. Sangro,et al.  Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[36]  Y. Yasuda,et al.  Cytoskeletal changes during epithelial-to-fibroblastoid conversion as a crucial mechanism of des-gamma-carboxy prothrombin production in hepatocellular carcinoma. , 2009, International journal of oncology.

[37]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[38]  M. Kudo,et al.  Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score) , 2003, Journal of Gastroenterology.

[39]  S. Kawasaki,et al.  Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. , 2003, Journal of hepatology.

[40]  J. Zucman‐Rossi,et al.  Hepatocellular carcinoma , 1998, Nature Reviews Disease Primers.

[41]  F. Izzo,et al.  A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients , 1998, Hepatology.